PW Medtech Group Limited disclosed in its latest Next Day Disclosure Return that it repurchased an additional 106,000 ordinary shares on 11 September 2026 via on-market transactions at HKD 0.97–0.975 per share, for a total consideration of HKD 0.10 million.

Including this purchase, the company has acquired 4.52 million shares since activating its current repurchase mandate on 26 June 2026. The cumulative volume represents 0.31% of the 1.43 billion shares outstanding when the mandate was approved, while utilising roughly 3.13% of the 144.29 million-share authorisation.

All 4.52 million repurchased shares are awaiting cancellation; consequently, PW Medtech’s issued share capital remains unchanged at 1.43 billion shares as of 11 September 2026. Repurchase prices over the period have ranged from HKD 0.91 to HKD 1.10 per share.

Under Hong Kong Stock Exchange rules, PW Medtech is subject to a 30-day moratorium on issuing new shares following the latest buy-back, ending on 11 October 2026.